Cargando…

Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4

The effect of in vivo administration of monoclonal anti-L3T4 antibody on the development of murine collagen-induced arthritis (CIA) was assessed. Treatment with anti-L3T4 resulted in a greater than 90% depletion of L3T4+ T cells in lymph nodes and spleen, an effect that appears entirely reversed 30...

Descripción completa

Detalles Bibliográficos
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 1985
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2187818/
https://www.ncbi.nlm.nih.gov/pubmed/3928802
_version_ 1782146263029907456
collection PubMed
description The effect of in vivo administration of monoclonal anti-L3T4 antibody on the development of murine collagen-induced arthritis (CIA) was assessed. Treatment with anti-L3T4 resulted in a greater than 90% depletion of L3T4+ T cells in lymph nodes and spleen, an effect that appears entirely reversed 30 d after treatment. Administration of anti- L3T4 before immunization with type II collagen resulted in a significant decrease in arthritis incidence and delayed onset of the disease while treatment begun after a strong anticollagen IgG humoral response was underway was not effective in altering disease expression. These results suggest a prominent role for L3T4+ T cells in the pathogenesis of CIA.
format Text
id pubmed-2187818
institution National Center for Biotechnology Information
language English
publishDate 1985
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-21878182008-04-17 Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4 J Exp Med Articles The effect of in vivo administration of monoclonal anti-L3T4 antibody on the development of murine collagen-induced arthritis (CIA) was assessed. Treatment with anti-L3T4 resulted in a greater than 90% depletion of L3T4+ T cells in lymph nodes and spleen, an effect that appears entirely reversed 30 d after treatment. Administration of anti- L3T4 before immunization with type II collagen resulted in a significant decrease in arthritis incidence and delayed onset of the disease while treatment begun after a strong anticollagen IgG humoral response was underway was not effective in altering disease expression. These results suggest a prominent role for L3T4+ T cells in the pathogenesis of CIA. The Rockefeller University Press 1985-09-01 /pmc/articles/PMC2187818/ /pubmed/3928802 Text en This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Articles
Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4
title Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4
title_full Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4
title_fullStr Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4
title_full_unstemmed Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4
title_short Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4
title_sort prevention of type ii collagen-induced arthritis by in vivo treatment with anti-l3t4
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2187818/
https://www.ncbi.nlm.nih.gov/pubmed/3928802